Insight Molecular Diagnostics logo
Insight Molecular Diagnostics
IMDX | NASDAQ
Chart Builder DCF Calculator
$1.86
-$0.28 (-13.08%)
At close: Nov 16, 2026, 4:00 PM ET
$1.53
-$0.33 (-17.74%)
After-hours: Nov 16, 2026, 7:55 PM ET

Insight Molecular Diagnostics Company Profile

Company profile explained

Company Profile

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

Key Executives

Name Position
Joshua Riggs President, Chief Executive Officer & Director
Michael D. West Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
Andrea Susan James Chief Financial Officer
Yuh-Min Chiang Chief Technology Officer
Donnie Purto SVP of Sales & Sales Operations
Ekkehard Schutz Chief Science Officer
James Liu Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer
Paul R. Billings FACP Consulting Chief Medical Officer
Peter Hong Vice President, General Counsel & Secretary
Sandra O'Donald Senior Vice President of Business Operations
Steven Tahmooressi Vice President of Marketing

Latest SEC Filings

Date Type Title
Sep 21, 2026 8-K Current Report
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Jul 24, 2026 S-8 Filing
Jul 06, 2026 4 Filing
Jul 06, 2026 4 Filing
Jul 06, 2026 4 Filing
Jun 17, 2026 8-K Current Report
Jun 15, 2026 4 Filing
Jun 15, 2026 4 Filing
View All SEC Filings ➞
Insight Molecular Diagnostics
Insight Molecular Diagnostics logo
Country United States
IPO Date Dec 30, 2015
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 57
CEO Joshua Riggs

Contact Details

2 International Plaza Dr. Nashville, Tennessee 37217 United States

Stock Details

Ticker Symbol IMDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001642380
CUSIP Number 68235C206
ISIN Number US68235C2061
SIC Code 2835

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.